#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3534	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2637	394.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1708	1708	C	512	C	457	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5386	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	391.6	0	.	n	.	0	T695C	SNP	695	695	T	1385	1385	C	405	C,G	349,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5386	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	391.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	2027	2027	A	469	A	425	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5386	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	391.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2661	2661	C	504	C,A	455,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5386	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	391.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3287	3287	T	455	T,G	406,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5386	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	391.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2735	2735	A	518	A,G,T	466,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	536	folP	852	852	100.0	folP.l15.c4.ctg.1	2244	71.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1390	1392	AGC	124;123;123	A;G;C	112;109;107	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1060	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3832	82.7	1	SNP	p	S91F	0	.	.	271	273	TCC	781	783	TCC	76;77;77	T;C;C,A	69;72;71,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1060	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3832	82.7	1	SNP	p	D95G	0	.	.	283	285	GAC	793	795	GAC	74;74;75	G;A;C	69;69;72	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1060	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3832	82.7	1	SNP	p	D95N	0	.	.	283	285	GAC	793	795	GAC	74;74;75	G;A;C	69;69;72	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	516	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1812	85.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	326	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1542	63.4	0	.	n	.	0	C187G	SNP	187	187	C	866	866	G	110	G	99	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1252	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3579	104.5	1	SNP	p	D86N	0	.	.	256	258	GAC	876	878	GAC	123;123;122	G;A;C	110;110;116	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1252	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3579	104.5	1	SNP	p	S87I	0	.	.	259	261	AGT	879	881	AGT	123;124;124	A;G;T,G	115;118;111,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1252	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3579	104.5	1	SNP	p	S87R	0	.	.	259	261	AGT	879	881	AGT	123;124;124	A;G;T,G	115;118;111,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1252	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3579	104.5	1	SNP	p	S87W	0	.	.	259	261	AGT	879	881	AGT	123;124;124	A;G;T,G	115;118;111,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1252	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3579	104.5	1	SNP	p	S88P	0	.	.	262	264	TCC	882	884	TCC	124;125;125	T;C;C	117;119;120	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1076	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2934	108.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1716	1718	GGC	126;126;127	G;G;C	113;114;112	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1481	1483	GCA	134;135;135	G,A,T;C;A,C	120,1,1;123;119,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1484	1486	ATC	135;135;135	A;T;C	122;113;120	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1496	1498	GTG	135;134;135	G,A;T;G,C	121,1;121;114,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1496	1498	GTG	135;134;135	G,A;T;G,C	121,1;121;114,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2000	2002	ACC	96;96;96	A;C;C	86;76;89	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2054	2056	GCG	93;91;92	G;C,A,G;G	76;67,1,1;72	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2054	2056	GCG	93;91;92	G;C,A,G;G	76;67,1,1;72	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2177	2179	GGC	94;95;95	G;G;C	80;85;83	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2186	2188	GGC	97;96;96	G;G;C	86;83;83	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2869	90.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2204	2206	CCG	96;96;95	C,G;C;G	83,2;81;80	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1166	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3697	94.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1900	1902	CTG	107;108;111	C,G;T;G	89,1;93;90	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	690	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2245	91.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	796	796	C	94	C	87	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	G38E	NONSYN	112	114	GGA	559	561	GAA	131;134;134	G;A;A	114;117;121	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	S46G	NONSYN	136	138	AGC	583	585	GGC	134;133;133	G;G;C	119;118;117	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	589	591	GGA	130;129;129	G;G;A	118;118;118	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	T87A	NONSYN	259	261	ACT	706	708	GCT	152;152;151	G;C;T	131;134;130	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	T89S	NONSYN	265	267	ACC	712	714	AGC	151;151;151	A;G;C	128;134;137	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	.	MULTIPLE	358	359	AA	804	805	CG	143;143	C;G	133;131	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	.	MULTIPLE	361	362	GA	807	809	CAG	139;140;139	C;A;G,C	128;130;131,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	N122K	NONSYN	364	366	AAC	811	813	AAA	139;139;139	A;A;A	131;129;127	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	K143E	NONSYN	427	429	AAA	874	876	GAA	149;149;147	G;A;A	137;133;131	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	V151A	NONSYN	451	453	GTA	898	900	GCA	151;152;151	G;C;A	141;141;140	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1006	1008	CGA	147;148;149	C;G;A	136;133;135	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1090	1092	ACT	151;151;151	A,G,C;C;T	135,1,1;135;137	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1093	1095	CAT	152;152;152	C;A;T	130;132;134	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1099	1101	ATG	151;151;151	A;T,G;G	138;135,2;134	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	.	MULTIPLE	766	767	AC	1213	1215	GCA	146;146;144	G;C;A	132;129;127	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1217	1219	CGG	144;145;145	C;G;G	128;128;127	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1220	1220	A	145	A	129	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	1	SNP	p	G120K	1	.	.	358	360	AAG	804	806	CGG	143;143;142	C;G;G	133;131;131	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	1	SNP	p	A121D	1	.	.	361	363	GAC	807	810	CGC	139;139;139	C;G,C;C,A	128;131,1;129,1	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	736	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1838	117.6	1	SNP	p	D121N	0	.	.	361	363	GAC	807	810	CGC	139;139;139	C;G,C;C,A	128;131,1;129,1	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2158	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5382	120.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2272	2274	AAT	114;114;114	A;A;T	106;107;106	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	378	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1502	75.3	1	SNP	p	V57M	1	.	.	169	171	ATG	748	750	ATG	136;136;136	A;T;G	123;123;121	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
